Cocrystal Pharma, Inc. (COCP)
NASDAQ: COCP · Real-Time Price · USD
1.095
-0.055 (-4.78%)
May 20, 2026, 1:25 PM EDT - Market open
Cocrystal Pharma Employees
Cocrystal Pharma had 10 employees as of December 31, 2025. The number of employees decreased by 1 or -9.09% compared to the previous year.
Employees
10
Change (1Y)
-1
Growth (1Y)
-9.09%
Revenue / Employee
$22,500
Profits / Employee
-$882,900
Market Cap
15.10M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 10 | -1 | -9.09% |
| Dec 31, 2024 | 11 | -1 | -8.33% |
| Dec 31, 2023 | 12 | 0 | - |
| Dec 31, 2022 | 12 | -1 | -7.69% |
| Dec 31, 2021 | 13 | 0 | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Quince Therapeutics | 38 |
| Passage Bio | 24 |
| SeaStar Medical Holding | 17 |
| IN8bio | 17 |
| NewcelX | 15 |
| Lipocine | 14 |
| Genenta Science | 9 |
| Exicure | 8 |
COCP News
- 5 days ago - Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results - GlobeNewsWire
- 19 days ago - Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection - GlobeNewsWire
- 26 days ago - Cocrystal Pharma files $150M mixed securities shelf - TheFly
- 6 weeks ago - Cocrystal Pharma receives FDA Fast Track designation for CDI-988 - TheFly
- 6 weeks ago - Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive - GlobeNewsWire
- 7 weeks ago - Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - GlobeNewsWire
- 2 months ago - Cocrystal Pharma announces first subjects dosed in Phase 1b study of CDI-988 - TheFly
- 2 months ago - First Subjects Dosed in Cocrystal Pharma's Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment - GlobeNewsWire